Drugs / Ataciguat
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT02481258 | Jun 2015 → Jul 2018 | aortic valve stenosis | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00799656 | Nov 2008 → Jun 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00443287 | Feb 2007 → Oct 2008 | intermittent vascular claudication | Sanofi | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07001800 | Jun 2025 → Aug 2028 expected | aortic valve stenosis | Kardigan, Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02049203 Comparator | Jan 2014 → Mar 2015 | aortic valve stenosis | Jordan D. Miller, Ph.D. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | Kardigan, Inc. | Results Kardigan Presents Positive Phase 2 Data on Ataciguat in Patients with Moderate Calcific Aortic Valve Stenosis at American Heart Association Scientific Sessions 2025 kardigan.bio ↗
Results demonstrated that treatment with ataciguat, an investigational oral soluble guanylate cyclase activator, slowed the progression of aortic valve calcium (AVC), leading to improvements in measures of valvular compliance, cardiac output (CO), and cardiac function when compared to placebo. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | Kardigan, Inc. | Kardigan Presents Positive Phase 2 Data on Ataciguat in Patients with Moderate Calcific Aortic Valve Stenosis at American Heart Association Scientific Sessions 2025 kardigan.bio ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ataciguat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02049203 ↗ |
| Known as | HMR1766 | “Drug: ataciguat (HMR1766)” NCT00799656 ↗ |
| Action | Restore | “reactivation of oxidized sGC (soluble guanylate cyclase), the primary receptor for nitric oxide, with ataciguat” PMID 39989354 ↗ Feb 2025 |
| Modality | Small molecule | — CHEMBL2107729 ↗ |
| Route | Oral | “oral administration” NCT00443287 ↗ |